Factor to reveal engineered iPSC-derived macrophages that enhance T cell cytotoxicity to triple negative breast and ovarian cancer cells Presentations will include latest preclinical data from Factor’s stealth iPSC and nucleic acid delivery platforms CAMBRIDGE, Mass., July 9, 2024…